Xenoport CFO Presents At Wedbush Securities Conference - Conference Call Transcript

XenoPort, Inc. (XNPT)

Life Sciences Management Access Conference Call

August 14, 2012 10:20 a.m. ET

Executives

William Harris – CFO

Analysts

Christopher Marai – Wedbush Securities

Presentation

Christopher Marai

Compare to:
Previous Statements by XNPT
» Xenoport's CEO Discusses Q2 2012 Results - Earnings Call Transcript
» XenoPort, Inc. Q2 2009 Earnings Call Transcript
» XenoPort, Inc., Q1 2009 Earnings Call Transcript.
» XenoPort Inc. Q4 2008 Earnings Call Transcript

Okay, good morning, thank you for joining us, my name is Chris Marai. I am an analyst here at Wedbush, I work with Greg Wade and David Nierengarten on the biotech team. This morning I would like to introduce XenoPort and Bill Harris their CFO. I’m going to leave it to Bill to describe some of the compelling opportunities ahead for XenoPort. Thank you.

William Harris

Thank you Chris, and thank you Wedbush for the invitation this week here today. Before I get started I would just like to remind you I will be making forward-looking statements that involves risks and uncertainties, and for more information regarding the risks and uncertainties of our business, please refer to the risk factor section of our current SEC filing.

I would like to start by touching on highlights of our business. Gabapentin enacarbil known as Horizant in the US and Regnite in Japan is approved to treat moderate to severe primary Restless Legs Syndrome or RLS in both US and Japan and recently received approval for the management of postherpetic neuralgia in the US.

Our most advanced product candidate [inaudible] is currently in a phase III trial in MS patients with spasticity, we expect top line results from this study in the first quarter of next year and assuming a positive outcome we expect to file an NDA under 505(b)(2) in the second half of next year.

1 2 3 Next › Last »